An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs ACH 4471 (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Proof of concept; Therapeutic Use
- Sponsors Achillion Pharmaceuticals
- 22 Feb 2018 According to an Achillion media release, interim data from this study is expected in fourth quarter 2018.
- 07 Nov 2017 New trial record
- 02 Nov 2017 According to Achillion media release, company plans to initiate the trial in first half of 2018.